114 related articles for article (PubMed ID: 8611558)
1. Mutational analysis of the endothelin type A receptor (ETA): interactions and model of selective ETA antagonist BMS-182874 with putative ETA receptor binding cavity.
Webb ML; Patel PS; Rose PM; Liu EC; Stein PD; Barrish J; Lach DA; Stouch T; Fisher SM; Hadjilambris O; Lee H; Skwish S; Dickinson KE; Krystek SR
Biochemistry; 1996 Feb; 35(8):2548-56. PubMed ID: 8611558
[TBL] [Abstract][Full Text] [Related]
2. Aspartate mutation distinguishes ETA but not ETB receptor subtype-selective ligand binding while abolishing phospholipase C activation in both receptors.
Rose PM; Krystek SR; Patel PS; Liu EC; Lynch JS; Lach DA; Fisher SM; Webb ML
FEBS Lett; 1995 Mar; 361(2-3):243-9. PubMed ID: 7698331
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of two novel mixed ETA/ETB receptor antagonists, BQ-928 and 238, in the carotid and pulmonary arteries and the perfused kidney of the rabbit.
Maurice MC; Gratton JP; D'Orléans-Juste P
Br J Pharmacol; 1997 Jan; 120(2):319-25. PubMed ID: 9117126
[TBL] [Abstract][Full Text] [Related]
4. Identification of specific intracellular domains of the human ETA receptor required for ligand binding and signal transduction.
Hashido K; Adachi M; Gamou T; Watanabe T; Furuichi Y; Miyamoto C
Cell Mol Biol Res; 1993; 39(1):3-12. PubMed ID: 8287069
[TBL] [Abstract][Full Text] [Related]
5. New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-N-pyridyl-,-N-pyrimidinyl-,-N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides.
Bradbury RH; Bath C; Butlin RJ; Dennis M; Heys C; Hunt SJ; James R; Mortlock AA; Sumner NF; Tang EK; Telford B; Whiting E; Wilson C
J Med Chem; 1997 Mar; 40(6):996-1004. PubMed ID: 9083490
[TBL] [Abstract][Full Text] [Related]
6. Ligand binding domain of the human endothelin-B subtype receptor.
Wada K; Hashido K; Terashima H; Adachi M; Fujii Y; Hiraoka O; Furuichi Y; Miyamoto C
Protein Expr Purif; 1995 Jun; 6(3):228-36. PubMed ID: 7663155
[TBL] [Abstract][Full Text] [Related]
7. BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist.
Webb ML; Bird JE; Liu EC; Rose PM; Serafino R; Stein PD; Moreland S
J Pharmacol Exp Ther; 1995 Mar; 272(3):1124-34. PubMed ID: 7891325
[TBL] [Abstract][Full Text] [Related]
8. Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptors.
Nambi P; Pullen M; Wu HL; Lee D; Saunders D; Heys R; Aiyar N; Leber J; Elliott J; Brooks D; Ohlstein E; Ruffolo R
J Pharmacol Exp Ther; 1996 Jun; 277(3):1567-71. PubMed ID: 8667224
[TBL] [Abstract][Full Text] [Related]
9. Novel endothelin receptors in the follicular membranes of Xenopus laevis oocytes mediate calcium responses by signal transduction through gap junctions.
Kumar CS; Nuthulaganti P; Pullen M; Nambi P
Mol Pharmacol; 1993 Jul; 44(1):153-7. PubMed ID: 8341269
[TBL] [Abstract][Full Text] [Related]
10. Functional and binding characterization of endothelin receptors in human bronchus: evidence for a novel endothelin B receptor subtype?
Hay DW; Luttmann MA; Pullen MA; Nambi P
J Pharmacol Exp Ther; 1998 Feb; 284(2):669-77. PubMed ID: 9454813
[TBL] [Abstract][Full Text] [Related]
11. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
[TBL] [Abstract][Full Text] [Related]
13. Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.
Fowler CB; Pogozheva ID; Lomize AL; LeVine H; Mosberg HI
Biochemistry; 2004 Dec; 43(50):15796-810. PubMed ID: 15595835
[TBL] [Abstract][Full Text] [Related]
14. Expression of endothelin and ETB receptors in the megakaryoblastic MEG-01 cell line.
Hamroun D; Mathieu MN; Clain E; Germani E; Laliberté MF; Laliberté F; Chevillard C
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S156-8. PubMed ID: 8587350
[TBL] [Abstract][Full Text] [Related]
15. Mutation of peptide binding site in transmembrane region of a G protein-coupled receptor accounts for endothelin receptor subtype selectivity.
Krystek SR; Patel PS; Rose PM; Fisher SM; Kienzle BK; Lach DA; Liu EC; Lynch JS; Novotny J; Webb ML
J Biol Chem; 1994 Apr; 269(17):12383-6. PubMed ID: 8175640
[TBL] [Abstract][Full Text] [Related]
16. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.
Ohlstein EH; Nambi P; Hay DW; Gellai M; Brooks DP; Luengo J; Xiang JN; Elliott JD
J Pharmacol Exp Ther; 1998 Aug; 286(2):650-6. PubMed ID: 9694916
[TBL] [Abstract][Full Text] [Related]
17. Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.
Astles PC; Brealey C; Brown TJ; Facchini V; Handscombe C; Harris NV; McCarthy C; McLay IM; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
J Med Chem; 1998 Jul; 41(15):2732-44. PubMed ID: 9667964
[TBL] [Abstract][Full Text] [Related]
18. Receptor-mediated effects of endothelin on the L-type Ca++ current in ventricular cardiomyocytes.
Kelso EJ; Spiers JP; McDermott BJ; Scholfield CN; Silke B
J Pharmacol Exp Ther; 1998 Aug; 286(2):662-9. PubMed ID: 9694918
[TBL] [Abstract][Full Text] [Related]
19. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
[TBL] [Abstract][Full Text] [Related]
20. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol.
Kowala MC; Rose PM; Stein PD; Goller N; Recce R; Beyer S; Valentine M; Barton D; Durham SK
Am J Pathol; 1995 Apr; 146(4):819-26. PubMed ID: 7717449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
